Treatment of Central Nervous System Infection Caused by Multidrug-Resistant
Acinetobacter baumannii
central nervous system infection
colistin
colistin sulfate
intraventricular administration
polymyxin
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
06
2023
accepted:
05
09
2023
medline:
18
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
Due to the spread of antimicrobial-resistant bacteria and poor penetration of many antimicrobial drugs across the blood-brain barrier following intravenous administration, treatment of central nervous system (CNS) infections is challenging, especially infections caused by carbapenem-resistant organisms (CRO). Intraventricular (IVT) infusion of antimicrobial drugs could be a choice. This report aims to describe a patient with CNS infection caused by carbapenem-resistant A case of CNS infection caused by CRAB after a craniocerebral injury was presented. The patient was treated with IVT together with IV colistin sulfate. Moreover, literature on the regimens and safety of colistin sulfate were also reviewed and summarized. Intraventricular (50,000 U, qd/100,000 U, qd) combined with IV (500,000 U, q12h/500,000 U, q8h) colistin sulfate was given to the patient, and the CNS infection was successfully controlled. The patient was finally transferred back to a local hospital for rehabilitation treatment. No nephrotoxicity or neurotoxicity was observed during the therapy. IV combined with IVT colistin sulfate is effective in the treatment of CNS infections caused by CRAB. IVT concomitant IV colistin sulfate might be a therapeutic option worth considering in the treatment of CNS infections caused by CRO.
Identifiants
pubmed: 37719653
doi: 10.2147/IDR.S425415
pii: 425415
pmc: PMC10503561
doi:
Types de publication
Case Reports
Langues
eng
Pagination
6029-6038Informations de copyright
© 2023 Yang et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest in this work.
Références
Ann Palliat Med. 2022 Feb;11(2):490-497
pubmed: 35249326
Int J Antimicrob Agents. 2018 Apr;51(4):646-650
pubmed: 29241820
Ann Transl Med. 2022 Oct;10(20):1137
pubmed: 36388829
Iran J Pediatr. 2015 Aug;25(4):e453
pubmed: 26396706
Trop Med Infect Dis. 2022 Mar 03;7(3):
pubmed: 35324588
J Neurosurg. 2018 Jan;128(1):262-271
pubmed: 28298047
Scand J Infect Dis. 2010 Apr;42(4):260-5
pubmed: 20085424
Zhonghua Shao Shang Za Zhi. 2009 Oct;25(5):372-6
pubmed: 19951562
Pharmaceuticals (Basel). 2022 Nov 29;15(12):
pubmed: 36558933
Pediatr Neonatol. 2022 Mar;63(2):190-191
pubmed: 35148977
Front Pharmacol. 2022 Aug 29;13:967412
pubmed: 36105229
J Antimicrob Chemother. 2006 Dec;58(6):1221-9
pubmed: 17012300
Clin Microbiol Infect. 2022 Apr;28(4):521-547
pubmed: 34923128
Int J Antimicrob Agents. 2007 Jan;29(1):9-25
pubmed: 17126534
Int J Antimicrob Agents. 2021 Mar;57(3):106281
pubmed: 33465459
Front Med (Lausanne). 2022 Dec 29;9:1067548
pubmed: 36643845
J Infect Dev Ctries. 2022 Jul 28;16(7):1226-1229
pubmed: 35905029
Int J Antimicrob Agents. 2015 Jan;45(1):8-18
pubmed: 25465524
Infect Drug Resist. 2022 Feb 28;15:697-721
pubmed: 35250284
Pharmacotherapy. 2019 Jan;39(1):10-39
pubmed: 30710469
Clin Infect Dis. 2017 Mar 15;64(6):e34-e65
pubmed: 28203777
Antibiotics (Basel). 2022 Oct 19;11(10):
pubmed: 36290098
J Int Med Res. 2020 Jul;48(7):300060520920405
pubmed: 32628870
Ann Palliat Med. 2022 Sep;11(9):2939-2951
pubmed: 36217623
Clin Infect Dis. 2013 Nov;57(9):1300-3
pubmed: 23840000
Int J Antimicrob Agents. 2013 Jun;41(6):499-508
pubmed: 23507414
Front Pharmacol. 2022 Jun 16;13:915958
pubmed: 35784679
Antimicrob Agents Chemother. 2013 Apr;57(4):1938-40
pubmed: 23335739
Infect Drug Resist. 2019 Jan 21;12:241-247
pubmed: 30718963
Br J Clin Pharmacol. 2022 Jul;88(7):3490-3494
pubmed: 35060164
Ann Palliat Med. 2021 Aug;10(8):9288-9296
pubmed: 34488415